Clinical Trial

Sacituzumab Govitecan for the Treatment for Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated February 24, 2026 (before its estimated March 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This phase II trial tests how well sacituzumab govitecan works in treating patients with cholangiocarcinoma that has spread to nearby tissue or lymph nodes (locally advanced), that has come back after a period of improvement (recurrent) or that has spread from where it first started (primary site) to other places in the body (metastatic). Sacituzumab govitecan is a monoclonal antibody, called hRS7, linked to a toxic agent, called SN-38. HRS7 is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of tumor cells, known as TROP2 receptors, and delivers SN-38 to kill them.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-12-20; most recent amendment 2026-02-20.
Status change: Recruiting → Active, Not Recruiting 2026-02-20
Status change: Not Yet Recruiting → Recruiting 2024-02-21
Trial Details
NCT Number NCT06178588
Lead Sponsor University of Kansas Medical Center
Collaborators: National Cancer Institute (NCI)
Conditions Locally Advanced Cholangiocarcinoma, Metastatic Cholangiocarcinoma, Recurrent Cholangiocarcinoma, Stage III Hilar Cholangiocarcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Hilar Cholangiocarcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8
Enrollment 15 participants
Start Date 2024-02-01
Primary Completion 2026-03-01 (estimated)
Study Completion 2026-11-01 (estimated)
Updated on ClinicalTrials.gov 2026-02-24